GT Biopharma (GTBP) Short Interest Ratio & Short Volume → World’s biggest multibillionaire investor is buying THIS by the ton [picture] (From Stansberry Research) (Ad) Free GTBP Stock Alerts $3.75 +0.10 (+2.74%) (As of 05:12 PM ET) Add Compare Share Share Short InterestStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media GT Biopharma Short Interest DataCurrent Short Volume3,300 sharesPrevious Short Volume8,800 sharesChange Vs. Previous Month-62.50%Dollar Volume Sold Short$12,408.00Short Interest Ratio / Days to Cover0.3Last Record DateApril 15, 2024Outstanding Shares1,381,000 sharesFloat Size1,240,000 sharesShort Percent of Float0.27%Today's Trading Volume3,434 sharesAverage Trading Volume11,704 sharesToday's Volume Vs. Average29% Short Selling GT Biopharma ? Sign up to receive the latest short interest report for GT Biopharma and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort InterestDays to CoverShort Percent of FloatGTBP Short Interest Over TimeGTBP Days to Cover Over TimeGTBP Percentage of Float Shorted Over Time Ad Traders Agencytop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.Click here now for the full details of this stock that’s set to rocket in the AI revolution… GT Biopharma Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 4/15/20243,300 shares $12,408.00 -62.5%0.3%0.3 $3.76 3/31/20248,800 shares $38,984.00 +79.6%0.7%0.7 $4.43 3/15/20244,900 shares $22,687.00 -14.0%0.4%0.4 $4.63 2/29/20245,700 shares $24,282.00 +72.7%0.5%0.6 $4.26 2/15/20243,300 shares $13,200.00 +312.5%0.3%0.4 $4.00 1/31/2024800 shares $4,752.00 -98.6%0.1%0.1 $5.94 Get the Latest News and Ratings for GTBP and Related StocksEnter your email address below to receive the latest news and analysts' ratings for GT Biopharma and its competitors with MarketBeat's FREE daily newsletter. 1/15/202458,800 shares $13,171.20 +150.2%0.2%0.4 $0.22 12/31/202323,500 shares $5,992.50 -64.8%0.1%0.2 $0.26 12/15/202366,800 shares $16,472.88 +14.8%0.2%0.6 $0.25 11/30/202358,200 shares $12,804.00 -62.3%0.2%0.5 $0.22 11/15/2023154,300 shares $37,032.00 +16.1%0.4%1.2 $0.24 10/31/2023132,900 shares $33,278.16 -16.8%0.4%0.9 $0.25 10/15/2023159,800 shares $40,749.00 +56.4%0.4%1 $0.26 9/30/2023102,200 shares $24,640.42 +122.2%0.3%0.4 $0.24 9/15/202346,000 shares $12,880.00 -12.9%0.1%0.1 $0.28 8/31/202352,800 shares $13,780.80 -76.7%0.1%0.1 $0.26 8/15/2023227,000 shares $59,996.10 +22.3%0.6%0.4 $0.26 7/31/2023185,600 shares $51,040.00 -15.6%0.5%0.3 $0.28 7/15/2023219,900 shares $73,402.62 -1.7%0.6%0.4 $0.33 6/30/2023223,600 shares $69,763.20 +9.3%0.6%0.4 $0.31 6/15/2023204,600 shares $71,589.54 +53.5%0.6%0.5 $0.35 5/31/2023133,300 shares $30,019.16 -5.7%0.4%0.5 $0.23 5/15/2023141,400 shares $42,391.72 -12.8%0.4%0.9 $0.30 1/29/2021102,800 shares $47,550.14 +411.4%N/A0.1 $0.46 1/15/202127,100 shares $13,818.29 +118.6%N/A0 $0.51 12/31/202010,200 shares $4,386.00 -62.4%N/A0 $0.43 12/15/202027,100 shares $7,859.00 +118.6%N/A0 $0.29 11/30/202012,400 shares $2,168.76 -34.7%N/A0 $0.17 11/15/202019,000 shares $3,467.50 -54.2%N/A0 $0.18 10/30/202041,500 shares $8,590.50 +24.3%N/A0.1 $0.21 10/15/202033,400 shares $6,680.00 +59.8%N/A0 $0.20 9/30/202020,900 shares $3,657.50 +770.8%N/A0.1 $0.18 9/15/20202,400 shares $408.00 -81.5%N/A0 $0.17 8/31/202013,000 shares $2,382.90 +20.4%N/A0.1 $0.18 8/14/202010,800 shares $1,922.40 -26.5%N/A0 $0.18 7/31/202014,700 shares $2,940.00 -30.7%N/A0 $0.20 7/15/202021,200 shares $4,452.00 -0.5%N/A0.1 $0.21 6/30/202021,300 shares $2,982.00 -47.4%N/A0.1 $0.14 6/15/202040,500 shares $8,505.00 +130.1%N/A0.3 $0.21 5/29/202017,600 shares $3,560.48 +175.0%N/A0.1 $0.20top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL) (Ad)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.Click here now for the full details of this stock that’s set to rocket in the AI revolution… GTBP Short Interest - Frequently Asked Questions What is GT Biopharma's current short interest? Short interest is the volume of GT Biopharma shares that have been sold short but have not yet been covered or closed out. As of April 15th, traders have sold 3,300 shares of GTBP short. 0.27% of GT Biopharma's shares are currently sold short. Learn More on GT Biopharma's current short interest. What is a good short interest percentage for GT Biopharma? Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 0.27% of GT Biopharma's floating shares are currently sold short. Is GT Biopharma's short interest increasing or decreasing? GT Biopharma saw a decline in short interest in the month of April. As of April 15th, there was short interest totaling 3,300 shares, a decline of 62.5% from the previous total of 8,800 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. What is GT Biopharma's float size? GT Biopharma currently has issued a total of 1,381,000 shares. Some of GT Biopharma's outstanding shares are available for trading, while others are subject to various restrictions. The public float, also referred to as floating shares or "the float", are shares that publicly owned, unrestricted and available to trade on the open market. GT Biopharma currently has a public float of 1,240,000 shares. How does GT Biopharma's short interest compare to its competitors? 0.27% of GT Biopharma's shares are currently sold short. Here is how the short interest of companies in the sector of "medical" compare to GT Biopharma: Oragenics, Inc. (2.07%), Synaptogenix, Inc. (3.21%), Alzamend Neuro, Inc. (0.30%), Bright Minds Biosciences Inc. (2.76%), PaxMedica, Inc. (9.41%), Processa Pharmaceuticals, Inc. (8.28%), ZyVersa Therapeutics, Inc. (6.14%), Kintara Therapeutics, Inc. (1.79%), NexImmune, Inc. (0.89%), Exicure, Inc. (2.01%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: T-Mobile US, Inc. ($3.70 billion), Occidental Petroleum Co. ($3.52 billion), Charter Communications, Inc. ($3.14 billion), General Motors ($2.68 billion), Coinbase Global, Inc. ($2.57 billion), Moderna, Inc. ($2.18 billion), Tractor Supply ($2.10 billion), Royal Caribbean Cruises Ltd. ($1.91 billion), TC Energy Co. ($1.90 billion), and Williams-Sonoma, Inc. ($1.78 billion). View all of the most shorted stocks. What does it mean to sell short GT Biopharma stock? Short selling GTBP is an investing strategy that aims to generate trading profit from GT Biopharma as its price is falling. GTBP shares are trading up $0.13 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against GT Biopharma? A short squeeze for GT Biopharma occurs when it has a large amount of short interest and its stock increases in price. This forces short sellers to cover their short interest positions by buying actual shares of GTBP, which in turn drives the price of the stock up even further. How often is GT Biopharma's short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including GTBP, twice per month. The most recent reporting period available is April, 15 2024. More Short Interest Resources from MarketBeat Related Companies: OGEN Short Interest Data SNPX Short Interest Data ALZN Short Interest Data DRUG Short Interest Data PXMD Short Interest Data PCSA Short Interest Data ZVSA Short Interest Data KTRA Short Interest Data NEXI Short Interest Data XCUR Short Interest Data Short Interest Tools: Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NASDAQ:GTBP) was last updated on 4/25/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThe Best AI Stock to Own in the World Today is Trading for Just $25Banyan Hill PublishingThese AI trades triggered this morning (545% return)Prosper Trading AcademyThe A.I. story nobody is telling you (Read ASAP)TradeSmithHe Is Giving Away BitcoinCrypto Swap Profitstop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyYour Money is Not SafeAmerican AlternativeThe only accurate crypto trading system I know …Weiss Ratings